Novo Nordisk says Wegovy coronary heart advantages because of greater than weight reduction
A zero.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is proven on this photograph representation in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Representation/Report Photograph Gain Licensing RightsPHILADELPHIA, Nov 11 (Reuters)